|
|
|
|
European Pharmaceutical Contractor |
| |
|
Published quarterly, European Pharmaceutical Contractor (EPC) covers the essential contract research issues between pharma companies and their CRO partners. The title, which is integrated within International Clinical Trials (ICT) magazine, offers a strategic view of the drug development industry – giving
its pharma, biotech, and CRO readership expert insight and
analysis on the sponsor-service provider landscape.
EPC focusses on key trends, concerns, and developments in contract research operations across the drug development spectrum, from preclinical to post-marketing. It explores the shifting collaborative needs and practical implications for sponsors and their contract partners, with the emphasis
on building and managing effective collaborations.
Prompted by the synergies between outsourcing and trial operations, EPC joined forces with sister brand ICT in late-2015, in a move that brings added value to both brands.
With EPC now an inserted edition within ICT, industry practitioners across these complementary subject areas
now have unrivalled access to a wealth of shared views
and analyses.
We're also on Twitter! Follow us @EPCmagazine
Read
our publications on the go in the Samedan app for phones and tablets. You
can download issues for offline reading, and our archives go as far back
as 2008! Download for free on the App Store, GooglePlay, or Amazon.   
|
|
|
|
 |
|
|
 |
Industry Events |
 |
SAPHEX 2019
23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA
SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention
Centre, Johannesburg, South Africa.
More info >> |
|
 |
News and Press Releases |
 |
MedPharm announce expansion of partnership with Palvella Therapeutics in developing a new treatment for the debilitating rare disease, pachyonychia congenita
MedPharm Ltd have announced the expansion of their partnership with Palvella Therapeutics, Inc., a Philadelphia-based biopharmaceutical company focused on developing and commercialising therapies for debilitating, rare genetic diseases. To date, MedPharm has employed its world-renowned specialist formulation expertise to support Palvella’s development of a novel, high-strength rapamycin topical formulation for application to the skin (PTX 022) as a disease-modifying treatment for pachyonychia congenita (PC). Most recently, MedPharm has made arrangements to manufacture the clinical (IMP) batches for use in Palvella’s upcoming Phase 2/3 clinical study.
More info >> |
|
 |
White Papers |
 |
|
Speciality Logistics Outlook 2015
World Courier
To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >> |
|
|
